Aditya Rawat: Clopidogrel, CYP2C19 and the Role of Pharmacogenetics
Aditya Rawat, Trainee Pharmacy Assistant at City Hospital and Research Centre, Haryana, India, shared a post on LinkedIn about recent article, Yo Han Jung et al, published in JAMA, adding:
“A drug only works if your body actually turns it on.
This week in Pharmacology we started on prodrugs.
These are medicines that are inactive as swallowed and need the liver to convert them.
Clopidogrel, a widely used antiplatelet after stroke and heart attack, is a classic example. Its activation depends heavily on one enzyme, CYP2C19.
I read a 2025 JAMA Network Open trial that followed 2,910 stroke patients in South Korea, all genotyped for CYP2C19.
61 percent carried a loss of function allele.
Over six months, carriers had more cardiovascular events than non carriers (2.7 percent vs 1.6 percent).
After adjustment, non carriers had roughly 42 percent lower risk, with no difference in bleeding.
What stood out to me:
- The common variants link straight back to molecular biology. 2 disrupts splicing and 3 introduces a premature stop codon.
- The absolute difference is small and the trial wasn’t randomised, so this supports, rather than proves, genotype guided prescribing.
- A platelet function test didn’t predict outcomes, but the genotype did.
It’s a neat case where pharmacokinetics, genetics and clinical outcomes all meet in one tablet.”
Title: Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke
Authors: Yo Han Jung, Tae-Jin Song, Jinkwon Kim, Hee-Kwon Park, Sang Won Han, Young Dae Kim, Jong-Ho Park, Jae-Kwan Cha, Hyun Young Park, Sung-Il Sohn, Sungwook Yu, Jun Hong Lee, Dong Hoon Shin, Eung-Gyu Kim, Hye Sun Lee, Kyung-Yul Lee
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support